Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
– MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression – First data readout expected in Q1/ 2024 with study completion planned for September 2024 Berlin, Germany, September 26, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced the successful […]
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
– First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally – Enrollment ongoing in Germany, Spain, the Netherlands, and the United Kingdom Berlin, Germany, June 28, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced an update on its […]
Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
– Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 — Dopavision, a clinical-stage company pioneering the development of digitally delivered light-based therapeutics, today announced the appointment of Prof. Dr. Jens Ellrich as Chief Scientific Officer. Jens Ellrich brings a wealth of scientific knowledge and extensive experience in […]
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company’s Advisory Board
– Former Head of Novartis’ Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 — Dopavision, a clinical-stage company pioneering the development of digital therapeutics, today announced the appointment of Dr. Dirk Sauer as Chairman of the Company’s Advisory Board. Dirk Sauer brings an exceptional track record […]
Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer
– Former Novartis ophthalmology program head significantly strengthens Dopavision’s management capabilities – Company recently initiated clinical trial of novel digital therapeutic for childhood myopia Berlin, Germany, May 25, 2022 — Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company’s Chief Executive Officer. […]
Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials
– Seventure Partners and Novartis Pharmaceuticals join as new investors – Transformative treatment for millions of children with myopia Berlin, Germany, July 14, 2021 — Dopavision, a company pioneering the development of digital therapeutics, today announced the closing of a €12 million Series A financing round. Seventure Partners led the round and was joined by […]
Dopavision presents new research at ARVO virtual conference
Dopavision is presenting its new research findings at the ARVO conference, which is held virtually this year. The ARVO conference is the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) and one of the largest research conferences in vision world-wide, gathering key opinion leaders and experts in ophthalmology and myopia from […]
Dopavision featured in German TV magazine 3sat NANO
Dopavision was featured in today’s edition of the TV science program NANO by German TV station 3sat. For some time, scientists have observed that myopia is increasing at an unprecedented rate. New evidence shows that changes in visual behavior at work, school and during leisure time are driving the increase in myopia. This trend is […]
Dopavision’s Tim Schilling to present at myopia webinights online seminar
Tim Schilling will present today in the virtual Myopia Webinights format on the state of research on the role of dopamine in myopia. Myopia Webinights is a series of online talks on the science around myopia, intervention possibilities, and managing myopia in daily clinical care. It is directed at scientists, ophthalmologists and optometrists, regularly draws […]
Digital health startup Dopavision raises €1.2 million seed investment
Fighting the global myopia epidemic with digital technology: Dopavision, a Berlin-based digital health startup, is developing an innovative treatment for one of the largest medical needs in the world. After winning German government funding of € 1.4 million in 2018, Dopavision has successfully attracted venture investors for a seed investment of € 1.2 million. Lead […]